Medistim Management
Management criteria checks 3/4
Medistim's CEO is Kari Krogstad, appointed in Sep 2009, has a tenure of 14.58 years. total yearly compensation is NOK7.21M, comprised of 42% salary and 58% bonuses, including company stock and options. directly owns 0.39% of the company’s shares, worth €1.08M. The average tenure of the management team and the board of directors is 9.3 years and 1.3 years respectively.
Key information
Kari Krogstad
Chief executive officer
kr7.2m
Total compensation
CEO salary percentage | 42.0% |
CEO tenure | 14.6yrs |
CEO ownership | 0.4% |
Management average tenure | 9.3yrs |
Board average tenure | 1.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | n/a | n/a | kr103m |
Dec 31 2023 | kr7m | kr3m | kr104m |
Sep 30 2023 | n/a | n/a | kr117m |
Jun 30 2023 | n/a | n/a | kr116m |
Mar 31 2023 | n/a | n/a | kr116m |
Dec 31 2022 | kr9m | kr3m | kr114m |
Sep 30 2022 | n/a | n/a | kr98m |
Jun 30 2022 | n/a | n/a | kr92m |
Mar 31 2022 | n/a | n/a | kr93m |
Dec 31 2021 | kr6m | kr3m | kr91m |
Sep 30 2021 | n/a | n/a | kr88m |
Jun 30 2021 | n/a | n/a | kr84m |
Mar 31 2021 | n/a | n/a | kr70m |
Dec 31 2020 | kr6m | kr3m | kr69m |
Sep 30 2020 | n/a | n/a | kr71m |
Jun 30 2020 | n/a | n/a | kr74m |
Mar 31 2020 | n/a | n/a | kr75m |
Dec 31 2019 | kr4m | kr3m | kr70m |
Sep 30 2019 | n/a | n/a | kr79m |
Jun 30 2019 | n/a | n/a | kr73m |
Mar 31 2019 | n/a | n/a | kr64m |
Dec 31 2018 | kr4m | kr2m | kr57m |
Sep 30 2018 | n/a | n/a | kr46m |
Jun 30 2018 | n/a | n/a | kr48m |
Mar 31 2018 | n/a | n/a | kr45m |
Dec 31 2017 | kr4m | kr2m | kr48m |
Compensation vs Market: Kari's total compensation ($USD655.66K) is about average for companies of similar size in the German market ($USD691.02K).
Compensation vs Earnings: Kari's compensation has been consistent with company performance over the past year.
CEO
Kari Krogstad (59 yo)
14.6yrs
Tenure
kr7,205,702
Compensation
Ms. Kari Eian Krogstad serves as Director at Vistin Pharma ASA since June 24, a2020. She has been the Chief Executive Officer of Medistim ASA since September 1, 2009 and serves as its President. Ms. Krogst...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & President | 14.6yrs | kr7.21m | 0.39% NOK 1.1m | |
Chief Financial Officer | no data | kr2.77m | 0.17% NOK 466.3k | |
Vice President of Operations & Manufacturing | no data | kr1.67m | no data | |
Vice President of Marketing | 13.7yrs | kr1.87m | 0.0087% NOK 24.3k | |
Chief Innovation Officer | 5yrs | kr1.91m | 0.043% NOK 119.5k | |
Chief Business Development Officer | 2yrs | kr1.68m | 0.032% NOK 89.7k | |
President of Medistim USA Inc | no data | kr3.63m | 0.011% NOK 30.4k | |
Vice President of Sales - APAC | no data | kr2.55m | 0.089% NOK 248.4k | |
Vice President of Sales EMEA | no data | kr1.79m | 0.015% NOK 42.5k | |
Managing Director of Medistim Norge AS | no data | kr1.83m | 0.019% NOK 52.6k |
9.3yrs
Average Tenure
59yo
Average Age
Experienced Management: MD1's management team is seasoned and experienced (9.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman | 24.3yrs | kr495.00k | 7.02% NOK 19.6m | |
Independent Director | less than a year | no data | no data | |
Independent Director | 1.3yrs | no data | no data | |
Independent Director | less than a year | no data | no data | |
Independent Director | 10.3yrs | kr300.00k | no data |
1.3yrs
Average Tenure
56yo
Average Age
Experienced Board: MD1's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.